U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C27H27N5O3.3C4H6O4
Molecular Weight 1293.3341
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of CP-724714 SESQUISUCCINATE

SMILES

OC(=O)CCC(O)=O.OC(=O)CCC(O)=O.OC(=O)CCC(O)=O.COCC(=O)NC\C=C\C1=CC=C2N=CN=C(NC3=CC(C)=C(OC4=CN=C(C)C=C4)C=C3)C2=C1.COCC(=O)NC\C=C\C5=CC=C6N=CN=C(NC7=CC(C)=C(OC8=CN=C(C)C=C8)C=C7)C6=C5

InChI

InChIKey=QCQCPVIRLYJQCG-NZTFDADUSA-N
InChI=1S/2C27H27N5O3.3C4H6O4/c2*1-18-13-21(8-11-25(18)35-22-9-6-19(2)29-15-22)32-27-23-14-20(7-10-24(23)30-17-31-27)5-4-12-28-26(33)16-34-3;3*5-3(6)1-2-4(7)8/h2*4-11,13-15,17H,12,16H2,1-3H3,(H,28,33)(H,30,31,32);3*1-2H2,(H,5,6)(H,7,8)/b2*5-4+;;;

HIDE SMILES / InChI

Molecular Formula C4H6O4
Molecular Weight 118.088
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C27H27N5O3
Molecular Weight 469.535
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description

CP 724714 is an orally bioavailable, quinazoline-based, selective small molecule inhibitor of the HER2/erbB2 receptor tyrosine kinase. The compound could have particular potential in the treatment of women with metastatic breast cancer, of which 25-30% over express HER2/erbB2. CP 724714 was in preclinical development with Pfizer.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
32.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PubMed

PubMed

TitleDatePubMed
Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: combined ligand and target-based approach.
2008 Jun 26
Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
2009 Apr
Patents

Patents

Sample Use Guides

In Vivo Use Guide
In phase I-II clinical trials subjects received CP-724,714 as continuous oral daily doses on 21-day cycles for a predefined maximal duration of 17 cycles (51 weeks). There was no washout between cycles. The starting dose level was 250 mg QD. In subsequent dose cohorts, 250 mg BID, 400 mg BID, and 250 mg TID were evaluated. The maximal tolerated dose was identified as 250 mg TID.
Route of Administration: Oral
In Vitro Use Guide
CP-724714 inhibits erbB2 receptor autophosphorylation in NIH 3T3 cells expressing a chimeric receptor consisting of the EGFR extracellular domain and the erbB2 intracellular domain (IC50 15 ng/ml) and in vitro growth of SKBr3 cells (IC50 25 ng/ml).
Substance Class Chemical
Created
by admin
on Tue Oct 22 07:37:35 UTC 2019
Edited
by admin
on Tue Oct 22 07:37:35 UTC 2019
Record UNII
D9MYY7U9N1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CP-724714 SESQUISUCCINATE
Common Name English
BUTANEDIOIC ACID, COMPD. WITH 2-METHOXY-N-((2E)-3-(4-((3-METHYL-4-((6-METHYL-3-PYRIDINYL)OXY)PHENYL)AMINO)-6-QUINAZOLINYL)-2-PROPEN-1-YL)ACETAMIDE (3:2)
Systematic Name English
2-METHOXY-N-((2E)-3-(4-(3-METHYL-4-(6-METHYL-3-PYRIDINYL)OXY)PHENYLAMINO)-(6-QUINAZOLINYL)-2-PROPENYL)-ACETAMIDE, BUTANEDIOIC ACID 2:3
Common Name English
Code System Code Type Description
PUBCHEM
11981427
Created by admin on Tue Oct 22 07:37:35 UTC 2019 , Edited by admin on Tue Oct 22 07:37:35 UTC 2019
PRIMARY
CAS
543681-31-8
Created by admin on Tue Oct 22 07:37:35 UTC 2019 , Edited by admin on Tue Oct 22 07:37:35 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY